RAM
CLDX icon

Riggs Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Riggs Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19
Closed -$798 – 671
2024
Q1 		$798 Buy
+19
New +$780 ﹤0.01% 459

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Riggs Asset Management's CLDX Position: Q2 2024 in Review

Riggs Asset Management sold out of Celldex Therapeutics (CLDX) in Q2 2024, closing a stake of 19 shares — an estimated $798 sold.

Riggs Asset Management first reported a position in CLDX in Q1 2024 and held it in 1 quarter. The position peaked at $798 in Q1 2024. 183 funds tracked by Wall St. Rank hold CLDX as of Q2 2024.

  • Riggs Asset Management reported no remaining Celldex Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Riggs Asset Management sold 19 Celldex Therapeutics shares in Q2 2024, an estimated $798.
  • Riggs Asset Management first reported a position in Celldex Therapeutics in Q1 2024 and held it in 1 quarter.
  • Riggs Asset Management's Celldex Therapeutics position peaked at $798 in Q1 2024.
  • 183 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2024.

Based on Riggs Asset Management's 13F filing for Q2 2024, filed 29 Jul 2024.